Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Several Cosentyx mechanism and immunization statements are consistent with the provided label excerpts (IL-17A, immunizations/live vaccines). However, many vaccination-related claims are general/interpretive and not supported by the provided prescribing information, and the response introduces additional hold/pause decision factors not stated in the label excerpts.
Category Scores
Accurate Statements
Cosentyx (secukinumab) is an immune-targeted therapy for plaque psoriasis.
1.1 Plaque Psoriasis indication for COSENTYX; 12.1 MOA describes selective binding to IL-17A.
Cosentyx controls plaque psoriasis by blocking IL-17A signaling.
12.1 Mechanism of Action: binds IL-17A and inhibits its interaction with IL-17 receptor; inhibits proinflammatory cytokines and chemokines.
Cosentyx may alter a patient's immune response to live vaccines.
5.7 Immunizations: 'COSENTYX may alter a patient's immune response to live vaccines.'
Avoid use of live vaccines in patients treated with COSENTYX.
5.7 Immunizations: 'Avoid use of live vaccines in patients treated with COSENTYX'.
Cosentyx affects immune signaling.
12.1 Mechanism of Action: secukinumab inhibits IL-17A interaction with its receptor and inhibits release of proinflammatory cytokines/chemokines.
Unsupported Statements
A vaccine’s goal is to train the immune system.
Not addressed in the provided label excerpts.
Cosentyx can dampen certain immune responses.
The label says secukinumab inhibits IL-17A interaction and may alter immune response to live vaccines, but the specific phrasing 'dampen certain immune responses' is not explicitly supported in the provided excerpts.
Vaccination might not produce the same strength of immune response in every person on IL-17 inhibitors.
No statement about variability of immune response strength to vaccination is included in the provided excerpts.
Vaccination is generally expected to be compatible with non-live vaccines because Cosentyx is not a live virus therapy.
The label excerpt only explicitly addresses live vaccines; no compatibility statement for non-live vaccines is provided.
The effect of vaccination can differ by vaccine type.
Not stated in the provided label excerpts.
A key safety concern with vaccination during IL-17 inhibitor therapy is whether vaccination increases infection risk or triggers flare-ups.
The provided label excerpts do not mention infection risk or psoriasis flare-ups specifically in relation to vaccination.
With IL-17 inhibitors like Cosentyx, main practical issues to watch for include whether psoriasis symptoms flare after vaccination.
Not stated in the provided label excerpts.
With IL-17 inhibitors like Cosentyx, main practical issues to watch for include whether typical vaccine side effects (fever, fatigue, injection-site reactions) are more pronounced.
No vaccine-specific adverse effect comparisons (fever/fatigue/injection-site) are stated in the provided label excerpts.
The provided information does not include vaccine-specific safety outcomes for Cosentyx.
This is an assessment about the dataset/summary rather than a label-supported claim; it is not stated as part of the prescribing information.
Whether a person should pause Cosentyx around the time of vaccination depends on vaccine type (live vs non-live).
The label excerpt instructs to avoid live vaccines during treatment but does not provide guidance about pausing/holding Cosentyx for vaccination timing.
Whether a person should pause Cosentyx around the time of vaccination depends on psoriasis severity and prior flare risk.
No label guidance provided in the excerpts regarding holding Cosentyx based on psoriasis severity or prior flare risk for vaccination.
Whether a person should pause Cosentyx around the time of vaccination depends on clinician guidance.
The label excerpt does not provide decision criteria or holding guidance for vaccination timing.
The provided information does not include recommendations on holding Cosentyx for vaccination timing.
Not a label-supported statement; it comments on absence of content rather than on label content.
Live vaccines are the main category that can conflict with immune-modifying treatments.
While live vaccines are mentioned, this broader generalization is not explicitly stated in the provided excerpt.
There is no basis in the provided information to say that vaccines reduce Cosentyx’s psoriasis effectiveness directly.
This is an interpretive negative claim about effectiveness that is not addressed in the provided label excerpts.
Cosentyx’s treatment effect is based on cytokine blockade.
The label states inhibition of IL-17A interaction and inhibition of release of proinflammatory cytokines and chemokines, but 'treatment effect is based on cytokine blockade' is not phrased verbatim or explicitly as the basis in the provided excerpt.
The provided information suggests that the more likely issue is the vaccine’s ability to generate a strong protective immune response while on immunomodulating therapy.
The label excerpt focuses on immune response alterations to live vaccines and avoiding live vaccines; it does not discuss the vaccine's ability to generate protective immunity as the 'more likely issue'.
Contradictions
Important Omissions
Specific label instruction to 'avoid use of live vaccines in patients treated with COSENTYX' (and recommendation to complete age-appropriate immunizations prior to initiating therapy).
Importance:
Moderate
No mention of patient counseling points that vaccination with live vaccines is not recommended during COSENTYX treatment and patients should inform the healthcare practitioner they are taking COSENTYX prior to vaccination.
Importance:
Moderate
The label indicates COSENTYX may alter a patient's immune response to live vaccines, but the response does not explicitly connect this to the label's live-vaccine avoidance directive in a precise way.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
The response includes multiple vaccination-related safety/management assertions (infection risk, flare-ups, side effect prominence, holding/pause timing criteria) that are not supported by the provided label excerpts. The only clear label-supported vaccination instruction is to avoid live vaccines and consider completing immunizations prior to starting therapy.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Partially Aligned
Primary Issue
Many immunization-related claims are generalized or operational (infection/flaring/holding decisions, non-live vaccine compatibility, vaccine-specific side effect severity) without support in the provided label excerpts.
Suggested Improvement
Limit vaccination statements to what the label excerpt supports: consider completing age-appropriate immunizations before starting, COSENTYX may alter immune response to live vaccines, and avoid live vaccines during treatment; optionally echo patient counseling that live vaccines are not recommended during COSENTYX and patients should inform the healthcare practitioner they are taking COSENTYX prior to vaccination.